Cover Image

Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372]

Saved in:

Bibliographic Details
Main Authors:	Tingting Jiang (Author), Guan Wang (Author), Yao Liu (Author), Lu Feng (Author), Meng Wang (Author), Jie Liu (Author), Yi Chen (Author), Liang Ouyang (Author)
Format:	Book
Published:	Elsevier, 2022-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers
by: Tingting Jiang, et al.
Published: (2021)

Author correction to 'Approved HIV reverse transcriptase inhibitors in the past decade' [Acta Pharmaceutica Sinica B 12 (2022) 1567-1590]
by: Guangdi Li, et al.
Published: (2023)

Author correction to "Immune-awakening Saccharomyces-inspired nanocarrier for oral target delivery to lymph and tumors" [Acta Pharmaceutica Sinica B 12 (2022) 4501-4518]
by: Yuling Mao, et al.
Published: (2024)

Author correction to "YPD-30, a prodrug of YPD-29B, is an oral small-molecule inhibitor targeting PD-L1 for the treatment of human cancer" [Acta Pharmaceutica Sinica B 12 (2022) 2845-2858]
by: Fangfang Lai, et al.
Published: (2023)

Author correction to "Identification of the dietary supplement capsaicin as an inhibitor of Lassa virus entry" [Acta Pharmaceutica Sinica B 10 (2020) 789-798]
by: Ke Tang, et al.
Published: (2024)

Radioligands for Tropomyosin Receptor Kinase (Trk) Positron Emission Tomography Imaging
by: Ralf Schirrmacher, et al.
Published: (2019)

Tropomyosin receptor kinase B (TrkB) signalling: targeted therapy in neurogenic tumours
by: Yuehua Li, et al.
Published: (2023)

Author correction to "Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles" [Acta Pharmaceutica Sinica B 12 (2022) 1523-1533]
by: Canhao Wu, et al.
Published: (2023)

Author correction to 'Discovery and identification of EIF2AK2 as a direct key target of berberine for anti-inflammatory effects' [Acta Pharmaceutica Sinica B 13 (2023) 2138-2151]
by: Wei Wei, et al.
Published: (2024)

Author correction to 'Cardamonin from a medicinal herb protects against LPS-induced septic shock by suppressing NLRP3 inflammasome' [Acta Pharmaceutica Sinica B 9 (2019) 734-744]
by: Zhilei Wang, et al.
Published: (2020)

Author correction to 'Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models' [Acta Pharmaceutica Sinica B 11 (2021) 1903-1913]
by: Ziru Yu, et al.
Published: (2023)

Author correction to 'Protective effects of VMY-2-95 on corticosterone-induced injuries in mice and cellular models' [Acta Pharmaceutica Sinica B 11(2021) 1903-1913]
by: Ziru Yu, et al.
Published: (2023)

Author correction to 'Establishment of pseudovirus infection mouse models for in vivo pharmacodynamics evaluation of filovirus entry inhibitors' [Acta Pharmaceutica Sinica B 8 (2018) 200-208]
by: Qing Chen, et al.
Published: (2020)

Author correction to 'Actively priming autophagic cell death with novel transferrin receptor-targeted nanomedicine for synergistic chemotherapy against breast cancer' [Acta Pharmaceutica Sinica B 2019; 9(5):1061-1077]
by: Dong Mei, et al.
Published: (2020)

Erratum to "Identification of anti-Mycobacterium tuberculosis agents targeting the interaction of bacterial division proteins FtsZ and SepFe" [Acta Pharmaceutica Sinica B 13 (2023) 2056-2070]
by: Hongjuan Zhang, et al.
Published: (2023)

Author correction to "A nanocleaner specifically penetrates the blood‒brain barrier at lesions to clean toxic proteins and regulate inflammation in Alzheimer's disease" [Acta Pharmaceutica Sinica B 12, (2021) 4032-4044]
by: Ting Lei, et al.
Published: (2022)

Author correction to 'TMEM16A inhibits angiotensin II-induced basilar artery smooth muscle cell migration in a WNK1-dependent manner' [Acta Pharmaceutica Sinica B 11 (2021) 3994-4007]
by: Huaqing Zheng, et al.
Published: (2023)

Author correction to 'Design, synthesis and biological evaluation of chalcone analogues with novel dual antioxidant mechanisms as potential anti-ischemic stroke agents' [Acta Pharmaceutica Sinica B 9 (2019) 335-350]
by: Jiabing Wang, et al.
Published: (2022)

Author correction to 'Mevalonate improves anti-PD-1/PD-L1 efficacy by stabilizing CD274 mRNA' [Acta Pharmaceutica Sinica B 13 (2023) 2585-2600]
by: Wenxin Zhang, et al.
Published: (2023)

Author correction to 'Multifunctional regulatory protein connective tissue growth factor (CTGF): A potential therapeutic target for diverse diseases' [Acta pharmaceutica sinica B 12 (2022) 1740-1760]
by: Minyang Fu, et al.
Published: (2022)

Author correction to 'Ruscogenin alleviates LPS-triggered pulmonary endothelial barrier dysfunction through targeting NMMHC IIA to modulate TLR4 signaling' [Acta Pharmaceutica Sinica B 12 (2022) 1198-1212]
by: Yunhao Wu, et al.
Published: (2022)

Author correction to "DNA damage repair promotion in colonic epithelial cells by andrographolide downregulated cGAS‒STING pathway activation and contributed to the relief of CPT-11-induced intestinal mucositis" [Acta Pharmaceutica Sinica B 12 (2022) 262-273]
by: Yuanyuan Wang, et al.
Published: (2023)

Author correction to 'Ablation of Akt2 and AMPKα2 rescues high fat diet-induced obesity and hepatic steatosis through Parkin-mediated mitophagy' [Acta Pharmaceutica Sinica B 11 (2021) 3508-3526]
by: Shuyi Wang, et al.
Published: (2023)

NTRK fusions in osteosarcoma are rare and non‐functional events
by: Baptiste Ameline, et al.
Published: (2020)

Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors
by: Jeongwan Kang, et al.
Published: (2020)

Author correction to "Coordinated regulation of BACH1 and mitochondrial metabolism through tumor targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy" [Acta Pharmaceutica Sinica B 12 (2022) 3934-3951]
by: Xuan Yang, et al.
Published: (2023)

Dermoscopic Features of Spitz Tumor With LMNA-NTRK1 Fusion
by: Ben J. Friedman, et al.
Published: (2020)

Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population
by: Ruiying Zhao, et al.
Published: (2021)

Author correction to 'Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo' [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965]
by: Linglong Deng, et al.
Published: (2023)

NTRK Fusions in a Sarcomas Series: Pathology, Molecular and Clinical Aspects
by: Vasiliki Siozopoulou, et al.
Published: (2022)

Brazilian Expert Consensus for NTRK Gene Fusion Testing in Solid Tumors
by: Mariana Petaccia de Macedo, et al.
Published: (2023)

Identification and characterization of the Cucurbitacins, a novel class of small-molecule inhibitors of Tropomyosin receptor kinase a
by: Yueling Zhong, et al.
Published: (2019)

Author correction to 'Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota Lactobacillus johnsonii and regulating macrophage anti-inflammatory activity in mice' [Acta Pharmaceutica Sinica B 13 (2023) 1164-1179]
by: Xiaoqing Fan, et al.
Published: (2023)

A case of thyroid carcinoma with mucinous features harboring ETV6-NTRK3 fusion: Expanding the morphologic spectrum of NTRK-rearranged thyroid carcinoma
by: Khaled A. Murshed, et al.
Published: (2022)

Identification of Trim24 as a new NTRK3 fusion partner in lung adenocarcinoma: Diagnostic challenges of a novel fusion
by: Almudena Santón, et al.
Published: (2022)

Pleomorphic xanthoastrocytoma with NTRK fusion presenting as spontaneous intracranial hemorrhage-case report and literature review
by: Yilong Wu, et al.
Published: (2024)

NTRK-fusion associated sarcoma: Identification of two cases with a distinct perineurioma-like pattern
by: Vanessa Young, et al.
Published: (2022)

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
by: Liu D, et al.
Published: (2018)

Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia
by: Erdel Martin, et al.
Published: (2011)

Do Small Molecules Activate the TrkB Receptor in the Same Manner as BDNF? Limitations of Published TrkB Low Molecular Agonists and Screening for Novel TrkB Orthosteric Agonists
by: Piotr Pankiewicz, et al.
Published: (2021)